Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A phase III study of abemaciclib (LY2835219) combined with fulvestrant in women with hormone receptor positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (MONARCH 2) Llombart, A., Toi, M., Klise, S. R., Frenzel, M., Chan, E. M., Sledge, G. W. AMER ASSOC CANCER RESEARCH. 2015
View details for DOI 10.1158/1538-7445.SABCS14-OT1-1-07
View details for Web of Science ID 000356730200082